To identify the drug candidates, researchers studied the genes of the novel coronavirus and how it infects human cells. The study was published on bioRxiv, a website for preprinted biology studies, and the researchers have submitted it to a journal for publication.
The researchers identified 69 drug candidates, 24 of which already are FDA-approved to treat other diseases such as cancer, Parkinson’s disease and hypertension.
Other drug candidates on the list include haloperidol, used to treat schizophrenia, and metformin, used by patients to help manage Type 2 diabetes.
The list also includes drug candidates that are in clinical trials, antibiotics that kill bacteria by targeting how they build proteins, and chloroquine, an antimalarial drug.
Chloroquine has received a lot of attention since last week, when President Donald Trump called the drug a “game changer” for COVID-19 at a news briefing at the White House.
Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, added a warning that there was only “anecdotal evidence” that chloroquine could help treat COVID-19, according to the report.
View the full list of 69 drug candidates, compounds here.
More articles on pharmacy:
CVS clarifies policies after 4,000+ workers petition for sick pay, protective gear
WHO launches clinical trial in 10 countries to find COVID-19 treatment
How top retail pharmacy chains have responded to the coronavirus pandemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.